ABC | Volume 114, Nº4, April 2020

Original Article Scherr et al. Interleukin-18 and thrombus precursor protein in CAD Arq Bras Cardiol. 2020; 114(4):692-698 Table 1 – Risk factors for CAD in the study groups Risk factors Group I Group II Group III Statistic test p n % n % n % SAH Yes 31 79.5 28 70.0 32 80.0 χ 2 =1.4 0.495 No 8 20.5 12 30.0 8 20.0 DLP Yes 16 41.0 32 80.0 18 45.5 χ 2 =14.8 0.001 No 23 59.0 8 20.0 22 55.0 DM Yes 12 30.8 10 25.0 8 20.0 χ 2 =1.2 0.544 No 27 69.2 30 75.0 32 80.0 SMOKER Yes 3 7.7 5 12.5 0 0.0 χ 2 =5 0.079 No 36 92.3 35 87.5 40 100.0 EX-SMOKER Yes 15 38.5 22 55.0 7 17.5 χ 2 =12.1 0.002 No 24 61.5 18 45.0 33 82.5 SEDENT Yes 38 97.4 31 77.5 31 77.5 χ 2 =7.7 0.021 No 1 2.6 9 22.5 13 22.5 OVER/OBES Yes 30 76.9 31 77.5 27 67.5 χ 2 =1.3 0.521 No 9 23.1 9 22.5 13 32.5 CRF Yes 2 5.1 2 5.0 0 0.0 χ 2 =2.0 0.351 No 37 94.9 38 95.0 40 100.0 Grupo I: pacientes agudos (SCA); Grupo II: pacientes crônicos (DAC); Grupo III: grupo-controle (com Risk factors para DAC, mas sem lesão coronariana); DAC: doença arterial coronariana; HAS: hipertensão arterial sistêmica; DLP: dislipidemia; DM: diabetes melito; TAB: tabagismo; Ex-TAB: ex-tabagismo; SEDENT: sedentarismo; SOB/OBES: sobrepeso/obesidade; IRC: insuficiência renal crônica. Corrigido pelo teste exato de Fisher. Table 2 – Means of the IL-18 and TpP biomarkers of the study groups Biomarkers Group I Group II Group III Statistic test p Comp. 2 by 2 IL-18 (pg/ml) 1325.44 353.81 633.25 F=6.61 0.002 GI>GII (±1860.13) (±273.65) (±993.93) GII=GIII GI>GIII TpT (µg/mL) 35.86±28.36 25.66±12.17 18.0±8.45 F=9.31 0.000 GI>GII GII=GIII GI>GIII 695